8P Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutant advanced NSCLC after progression on osimertinib: Secondary analyses of patient-relevant endpoints from MARIPOSA-2

Amivantamab (ami) is an EGFR-MET bispecific antibody with immune cell-directing activity. In MARIPOSA-2 (NCT04988295), ami plus carboplatin-pemetrexed (ami-chemo) significantly prolonged progression-free survival (PFS) vs chemo (HR, 0.48; P<0.001) in patients (pts) with EGFR-mutant advanced NSCLC after progression on osimertinib (Passaro Ann Oncol 2023). We evaluated time to symptomatic progression (TTSP) and patient-reported outcomes (PROs) from MARIPOSA-2. Analyses included 131 pts randomized to ami-chemo and 263 pts to chemo (intent-to-treat population [ITT]) who died or discontinued treatment. TTSP was defined as time from randomization to onset of new/worsening lung cancer symptoms requiring change in anticancer therapy, another clinical intervention, or death, whichever occurred first. PROs were measured using EORTC-QLQ-C30, NSCLC-SAQ, and PROMIS-PF 8c instruments; P values were nominal. At a median follow-up of 8.7 mo, a trend towards improvement in TTSP was observed for ami-chemo vs chemo (median, 14.9 vs 13.0 mo; HR, 0.74 [95% CI, 0.51–1.07]; P=0.10). Median treatment duration was 6.3 mo for ami-chemo vs 3.7 mo for chemo. At 6 mo (189 days), the percentage of ITT pts who remained on treatment and had improved or stable physical functioning relative to baseline was 37% for ami-chemo vs 21% for chemo; P<0.01). There were higher percentages of pts with improved or stable emotional functioning (38% vs 21%; P<0.01), cognitive functioning (38% vs 20%; P<0.01), role functioning (30% vs 19%; P=0.2), and global health status (40% vs 19%; P<0.01) for ami-chemo vs chemo, respectively. Based on data from EORTC-QLQ-C30, at 6 mo 28% vs 13% pts reported no dyspnea (P<0.01), 23% vs 15% reported no pain (P<0.05), and 10% vs 5% reported no fatigue for ami-chemo vs chemo (P>0.05), respectively. Updated results will include data from the NSCLC-SAQ and PROMIS-PF 8c instruments. Ami-chemo numerically prolonged TTSP vs chemo. More pts in the ITT population reported improved or stable functioning and absence of lung cancer-related symptoms for ami-chemo vs chemo in pts with EGFR-mutant advanced NSCLC after disease progression on osimertinib.